Barclays’s IN8bio INAB Stock Holding History

Barclays’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39	Buy	+28	New	+$42	﹤0.01%	5258
2024 Q4	–	Sell	-3	Closed	-$28	–	5372
2024 Q3	$28	Buy	+3	New	+$54	﹤0.01%	5224

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's INAB Position: Q2 2026 in Review

Barclays opened a new position in IN8bio (INAB) in Q2 2026: 28 shares worth $39. The stake represents ﹤0.01% of the portfolio and ranks #5258 among its holdings. This is a return to the name: Barclays previously reported a position in INAB as recently as Q3 2024.

Barclays first reported a position in INAB in Q3 2024 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

Barclays held 28 shares of IN8bio worth $39 as of Q2 2026.
IN8bio was a new Barclays position in Q2 2026.
IN8bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5258 holding.
Barclays first reported a position in IN8bio in Q3 2024 and has held it in 2 quarters since.
21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.